JP2020533334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533334A5 JP2020533334A5 JP2020514257A JP2020514257A JP2020533334A5 JP 2020533334 A5 JP2020533334 A5 JP 2020533334A5 JP 2020514257 A JP2020514257 A JP 2020514257A JP 2020514257 A JP2020514257 A JP 2020514257A JP 2020533334 A5 JP2020533334 A5 JP 2020533334A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai agent
- agent according
- nucleotides
- composition
- sense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023051640A JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285009A JP2026042849A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285010A JP2026042850A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556818P | 2017-09-11 | 2017-09-11 | |
| US62/556,818 | 2017-09-11 | ||
| US201862643927P | 2018-03-16 | 2018-03-16 | |
| US62/643,927 | 2018-03-16 | ||
| US201862720434P | 2018-08-21 | 2018-08-21 | |
| US62/720,434 | 2018-08-21 | ||
| PCT/US2018/050248 WO2019051402A1 (en) | 2017-09-11 | 2018-09-10 | RNA INTERFERENCE AGENTS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023051640A Division JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533334A JP2020533334A (ja) | 2020-11-19 |
| JP2020533334A5 true JP2020533334A5 (enExample) | 2021-10-07 |
| JP7438103B2 JP7438103B2 (ja) | 2024-02-26 |
Family
ID=65630632
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514257A Active JP7438103B2 (ja) | 2017-09-11 | 2018-09-10 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2023051640A Withdrawn JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285009A Pending JP2026042849A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285010A Pending JP2026042850A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023051640A Withdrawn JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285009A Pending JP2026042849A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285010A Pending JP2026042850A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US10597657B2 (enExample) |
| EP (1) | EP3681516A4 (enExample) |
| JP (4) | JP7438103B2 (enExample) |
| KR (2) | KR20240161202A (enExample) |
| CN (2) | CN111107853B (enExample) |
| AU (2) | AU2018329190B2 (enExample) |
| BR (1) | BR112020002413A2 (enExample) |
| CA (1) | CA3074303A1 (enExample) |
| CL (2) | CL2020000593A1 (enExample) |
| CO (1) | CO2020002586A2 (enExample) |
| CR (1) | CR20200108A (enExample) |
| EC (1) | ECSP20017905A (enExample) |
| IL (2) | IL273172B2 (enExample) |
| JO (1) | JOP20200054A1 (enExample) |
| MX (2) | MX2020002648A (enExample) |
| MY (1) | MY202025A (enExample) |
| NZ (1) | NZ763172A (enExample) |
| PE (1) | PE20201283A1 (enExample) |
| PH (1) | PH12020500332A1 (enExample) |
| SG (1) | SG11201912178VA (enExample) |
| TN (1) | TN2020000039A1 (enExample) |
| TW (2) | TWI811238B (enExample) |
| UY (1) | UY37871A (enExample) |
| WO (1) | WO2019051402A1 (enExample) |
| ZA (1) | ZA202100806B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017535552A (ja) | 2014-11-17 | 2017-11-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法 |
| SG11201901841TA (en) * | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| DK3607069T3 (da) | 2017-04-05 | 2022-11-21 | Silence Therapeutics Gmbh | Produkter og sammensætninger |
| KR20240161202A (ko) * | 2017-09-11 | 2024-11-12 | 애로우헤드 파마슈티컬스 인코포레이티드 | 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물 |
| EP3719126B1 (en) | 2017-12-01 | 2025-01-01 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
| WO2020135673A1 (zh) * | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| US12590304B2 (en) | 2019-05-22 | 2026-03-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| KR20220011689A (ko) | 2019-05-22 | 2022-01-28 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| MX2022001460A (es) * | 2019-08-05 | 2022-02-22 | Arrowhead Pharmaceuticals Inc | Metodos para el tratamiento de enfermedades y trastornos relacionados con apoc3. |
| JP7735288B2 (ja) | 2020-02-18 | 2025-09-08 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法 |
| CN114480382A (zh) * | 2020-11-12 | 2022-05-13 | 北京大学 | 用于抑制SURF4基因表达的RNAi试剂和组合物 |
| EP4176061A1 (en) * | 2021-01-30 | 2023-05-10 | E-Therapeutics plc | Nucleic acids containing abasic nucleotides |
| AU2022212580A1 (en) * | 2021-01-30 | 2023-07-27 | E-Therapeutics Plc | Nucleic acids containing abasic nucleotides |
| AU2022299514A1 (en) * | 2021-06-24 | 2024-01-18 | Sirnaomics, Inc. | Products and compositions |
| EP4372085A4 (en) * | 2021-07-16 | 2026-01-21 | Suzhou Ribo Life Science Co Ltd | Nucleic acid, composition and conjugate, container, preparation process and use |
| WO2023059948A1 (en) * | 2021-10-08 | 2023-04-13 | E-Therapeutics Plc | Nucleic acids containing abasic nucleosides |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| JP2024543195A (ja) | 2021-12-01 | 2024-11-19 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ａｐｏｃ３発現を調節するための組成物及び方法 |
| TW202340469A (zh) * | 2022-01-20 | 2023-10-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一種ｄｓｒｎａ、其應用及製備方法 |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| CN117756866A (zh) | 2022-01-30 | 2024-03-26 | 大睿生物医药科技(上海)有限公司 | 含有n-乙酰半乳糖胺的靶向配体 |
| CN119487191A (zh) | 2022-06-14 | 2025-02-18 | 大睿生物医药科技(上海)有限公司 | 调控PCSK9基因活性的siRNA分子 |
| CN119421952A (zh) * | 2022-06-27 | 2025-02-11 | 大睿生物医药科技(上海)有限公司 | 抑制载脂蛋白C3表达的siRNA |
| EP4555088A1 (en) * | 2022-07-11 | 2025-05-21 | Sanegene Bio USA Inc. | Optimized 2'- modified ribose derivatives and methods of use |
| AU2023313030A1 (en) * | 2022-07-27 | 2025-01-09 | E-Therapeutics Plc | Nucleic acid compounds |
| CN120615125A (zh) * | 2022-07-27 | 2025-09-09 | e-生物有限公司 | 核酸化合物 |
| CN120322552A (zh) * | 2022-07-27 | 2025-07-15 | e-生物有限公司 | 核酸化合物 |
| CN116814621B (zh) * | 2022-08-05 | 2025-09-09 | 厦门甘宝利生物医药有限公司 | 一种抑制apoc3基因表达的rna抑制剂及其应用 |
| CN119744305A (zh) * | 2022-08-11 | 2025-04-01 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
| WO2024165571A2 (en) * | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2024165568A2 (en) * | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2024188173A1 (zh) * | 2023-03-10 | 2024-09-19 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及其用途 |
| WO2025007961A1 (zh) | 2023-07-06 | 2025-01-09 | 大睿生物 | 调控AGT表达的dsRNA分子 |
| TW202526017A (zh) | 2023-09-14 | 2025-07-01 | 美商Ionis製藥公司 | 用於減少ａｐｏｃｉｉｉ表現的化合物及方法 |
| WO2025087442A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| WO2025125576A2 (en) * | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) * | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025133348A1 (en) * | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025184301A1 (en) * | 2024-02-29 | 2025-09-04 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for dual inhibition of expression of apolipoprotein c-iii (apoc3) and proprotein convertase subtilisin kexin 9 (pcsk9), compositions thereof, and methods of use |
| WO2025237176A1 (zh) * | 2024-05-11 | 2025-11-20 | 深圳信立泰药业股份有限公司 | 用于抑制GPR75基因表达的RNAi剂及其制备方法和用途 |
| KR20260032888A (ko) * | 2024-08-30 | 2026-03-10 | 올릭스 주식회사 | APOC3 유전자를 표적으로 하는 RNAi 제제 및 이의 용도 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| EP1399189A1 (en) | 2001-06-11 | 2004-03-24 | Universite De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| JP5170934B2 (ja) | 2001-08-16 | 2013-03-27 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 改良ｄｎａリポフェクションならびに／または徐放性プロドラッグおよび薬物療法のための試薬の合成と使用 |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| US20050008617A1 (en) | 2002-09-28 | 2005-01-13 | Massachusetts Institute Of Technology | Compositions and methods for delivery of short interfering RNA and short hairpin RNA |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| EP1585756B1 (en) | 2002-11-26 | 2010-04-21 | University of Massachusetts | Delivery of sirnas |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| CA2532228C (en) | 2003-07-16 | 2017-02-14 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| EP1660657A1 (en) | 2003-08-28 | 2006-05-31 | Novartis AG | Interfering rna duplex having blunt-ends and 3'-modifications |
| WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| WO2007107162A2 (en) | 2006-03-23 | 2007-09-27 | Santaris Pharma A/S | Small internally segmented interfering rna |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| KR101629017B1 (ko) | 2007-05-22 | 2016-06-10 | 아크투루스 쎄라퓨틱스, 인크. | 히드록시메틸 치환된 ｒｎａ 올리고뉴클레오티드 및 ｒｎａ 복합체 |
| US7615374B2 (en) | 2007-09-25 | 2009-11-10 | Wisconsin Alumni Research Foundation | Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions |
| ES2535419T3 (es) | 2007-12-27 | 2015-05-11 | Protiva Biotherapeutics Inc. | Silenciamiento de expresión de quinasa tipo polo usando ARN interferente |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| US9023820B2 (en) * | 2009-01-26 | 2015-05-05 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein C-III expression |
| CA3009891C (en) | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| SI2539451T1 (sl) | 2010-02-24 | 2016-04-29 | Arrowhead Research Corporation | Sestavki za ciljano dostavo sirna |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| MX390699B (es) | 2011-06-21 | 2025-03-21 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3). |
| WO2013032829A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| CA2842041A1 (en) | 2012-04-18 | 2013-10-24 | Arrowhead Research Corporation | Poly(acrylate) polymers for in vivo nucleic acid delivery |
| US20150299696A1 (en) * | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| EP3564374A1 (en) * | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| EP3736334A1 (en) * | 2014-07-16 | 2020-11-11 | Arrowhead Pharmaceuticals, Inc. | Rnai compositions to treat apoc3-related diseases |
| JP2017535552A (ja) * | 2014-11-17 | 2017-11-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法 |
| WO2016149020A1 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Rna interference agents |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| CA3011946A1 (en) | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| JP2020522510A (ja) * | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| KR20240161202A (ko) * | 2017-09-11 | 2024-11-12 | 애로우헤드 파마슈티컬스 인코포레이티드 | 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물 |
-
2018
- 2018-09-10 KR KR1020247035695A patent/KR20240161202A/ko active Pending
- 2018-09-10 CN CN201880059004.3A patent/CN111107853B/zh active Active
- 2018-09-10 US US16/126,740 patent/US10597657B2/en active Active
- 2018-09-10 SG SG11201912178VA patent/SG11201912178VA/en unknown
- 2018-09-10 PE PE2020000340A patent/PE20201283A1/es unknown
- 2018-09-10 JO JOP/2020/0054A patent/JOP20200054A1/ar unknown
- 2018-09-10 EP EP18853495.2A patent/EP3681516A4/en active Pending
- 2018-09-10 CA CA3074303A patent/CA3074303A1/en active Pending
- 2018-09-10 KR KR1020207006708A patent/KR102723833B1/ko active Active
- 2018-09-10 WO PCT/US2018/050248 patent/WO2019051402A1/en not_active Ceased
- 2018-09-10 IL IL273172A patent/IL273172B2/en unknown
- 2018-09-10 AU AU2018329190A patent/AU2018329190B2/en active Active
- 2018-09-10 MX MX2020002648A patent/MX2020002648A/es unknown
- 2018-09-10 CR CR20200108A patent/CR20200108A/es unknown
- 2018-09-10 CN CN202410900721.1A patent/CN118879696A/zh active Pending
- 2018-09-10 BR BR112020002413-9A patent/BR112020002413A2/pt unknown
- 2018-09-10 JP JP2020514257A patent/JP7438103B2/ja active Active
- 2018-09-10 TN TNP/2020/000039A patent/TN2020000039A1/en unknown
- 2018-09-10 NZ NZ763172A patent/NZ763172A/en unknown
- 2018-09-10 MY MYPI2020001153A patent/MY202025A/en unknown
- 2018-09-11 TW TW107131910A patent/TWI811238B/zh active
- 2018-09-11 UY UY0001037871A patent/UY37871A/es active IP Right Grant
- 2018-09-11 TW TW112125927A patent/TW202415389A/zh unknown
-
2020
- 2020-01-31 US US16/778,188 patent/US11214801B2/en active Active
- 2020-02-13 PH PH12020500332A patent/PH12020500332A1/en unknown
- 2020-03-04 CO CONC2020/0002586A patent/CO2020002586A2/es unknown
- 2020-03-06 MX MX2025015219A patent/MX2025015219A/es unknown
- 2020-03-09 CL CL2020000593A patent/CL2020000593A1/es unknown
- 2020-03-11 EC ECSENADI202017905A patent/ECSP20017905A/es unknown
-
2021
- 2021-02-05 ZA ZA2021/00806A patent/ZA202100806B/en unknown
- 2021-11-18 US US17/529,364 patent/US20220064646A1/en not_active Abandoned
-
2022
- 2022-12-22 US US18/145,218 patent/US12365899B2/en active Active
-
2023
- 2023-03-28 JP JP2023051640A patent/JP2023073358A/ja not_active Withdrawn
-
2024
- 2024-11-13 CL CL2024003470A patent/CL2024003470A1/es unknown
-
2025
- 2025-06-18 US US19/242,305 patent/US20260043025A1/en active Pending
- 2025-10-26 IL IL324223A patent/IL324223A/en unknown
- 2025-11-11 AU AU2025267315A patent/AU2025267315A1/en active Pending
- 2025-12-26 JP JP2025285009A patent/JP2026042849A/ja active Pending
- 2025-12-26 JP JP2025285010A patent/JP2026042850A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533334A5 (enExample) | ||
| JP2020534268A5 (enExample) | ||
| JP2022501040A5 (enExample) | ||
| TWI811238B (zh) | 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物 | |
| JP2018529732A5 (enExample) | ||
| JP6370860B2 (ja) | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2023519246A5 (enExample) | ||
| JP2022501040A (ja) | １７β−ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 | |
| CN104994884B (zh) | 对脂蛋白脂肪酶缺乏(lpld)群体中的载脂蛋白c-iii(apociii)表达的调节 | |
| JP2019518037A (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| JP2020526192A5 (enExample) | ||
| JP2023536999A (ja) | Ｂ型肝炎患者のオリゴヌクレオチド処置 | |
| JP7829478B2 (ja) | Ａｐｏｃ３関連疾患および障害の処置のための方法 | |
| JP2017510583A (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JP2020537653A5 (enExample) | ||
| JP7846095B2 (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| JP2018511555A (ja) | リポジストロフィー集団におけるアポリポタンパク質Ｃ−ＩＩＩ（ＡｐｏＣＩＩＩ）発現の調節 | |
| JP2025513757A5 (enExample) | ||
| JP2025507751A (ja) | アンジオポエチン様３（ａｎｇｐｔｌ３）関連状態を処置するための方法および組成物 | |
| TH2001001206A (th) | RNAi เอเจนท์และองค์ประกอบสำหรับการยับยั้งการแสดงออกของอะโปลิโพโปรตีน C-II (APOC3) | |
| AU2024345844A1 (en) | Compounds and methods for inhibiting lpa | |
| NZ763275B2 (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
| TW202546228A (zh) | 用於抑制胰島素樣生長因子１受體表達的ｒｎａ抑制劑 | |
| WO2025064815A1 (en) | Compounds and methods for inhibiting lpa |